FCH
SRNE

Freestone Capital Holdings’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Freestone Capital Holdings’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$6.83K – 1226
2020
Q4 		$6.83K Hold
1,000
– – ﹤0.01% 929
2020
Q3 		$11.2K Buy
+1,000
New +$9.15K ﹤0.01% 725

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Freestone Capital Holdings's SRNE Position: Q1 2021 in Review

Freestone Capital Holdings sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2021, closing a stake of 1,000 shares — an estimated $6.83K sold.

Freestone Capital Holdings first reported a position in SRNE in Q3 2020 and held it in 2 quarters. The position peaked at $11.2K in Q3 2020. 231 funds tracked by Wall St. Rank hold SRNE as of Q1 2021.

  • Freestone Capital Holdings reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2021 after selling out during the quarter.
  • Freestone Capital Holdings sold 1,000 Sorrento Therapeutics, Inc. shares in Q1 2021, an estimated $6.83K.
  • Freestone Capital Holdings first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 2 quarters.
  • Freestone Capital Holdings's Sorrento Therapeutics, Inc. position peaked at $11.2K in Q3 2020.
  • 231 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2021.

Based on Freestone Capital Holdings's 13F filing for Q1 2021, filed 17 May 2021.